Adial Pharmaceuticals, Inc.: 10-Q filed 2022-11-14

Name: Adial Pharmaceuticals, Inc.: 10-Q filed 2022-11-14
Creator: Adial Pharmaceuticals, Inc.

What Adial Pharmaceuticals, Inc. reported in its quarterly report filed 2022-11-14 (fiscal Q3 2022): 37 published measures, 102 facts as tagged in accession 0001213900-22-071643.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-14
Fiscal period: fiscal Q3 2022
Accession: 0001213900-22-071643 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Adial Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	7,741,684	USD
At 2021-12-31	7,474,975	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	2,332,639	USD
At 2021-12-31	3,967,164	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	5,409,045	USD
At 2022-06-30	7,961,380	USD
At 2022-03-31	10,707,325	USD
At 2021-12-31	3,507,811	USD
At 2021-09-30	7,200,098	USD
At 2021-06-30	4,829,003	USD
At 2021-03-31	5,617,642	USD
At 2020-12-31	3,986,066	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2022-09-30	5,752,665	USD
At 2021-12-31	6,062,173	USD
At 2020-12-31	4,401,114	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-3,109,350	USD	92
2022-01-01 to 2022-09-30	-9,864,721	USD	273
2022-04-01 to 2022-06-30	-3,847,532	USD	91
2022-01-01 to 2022-03-31	-2,907,839	USD	90
2021-07-01 to 2021-09-30	-4,317,784	USD	92
2021-01-01 to 2021-09-30	-13,592,482	USD	273
2021-04-01 to 2021-06-30	-4,440,934	USD	91
2021-01-01 to 2021-03-31	-4,833,764	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-9,435,114	USD	273
2021-01-01 to 2021-09-30	-9,576,397	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	64,605	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	9,125,606	USD	273
2021-01-01 to 2021-09-30	12,389,505	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	-34,016	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-60,807,836	USD
At 2021-12-31	-50,943,115	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	25,724,557	shares	92
2022-01-01 to 2022-09-30	24,803,909	shares	273
2021-07-01 to 2021-09-30	19,848,108	shares	92
2021-01-01 to 2021-09-30	17,864,604	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	25,724,557	shares	92
2022-01-01 to 2022-09-30	24,803,909	shares	273
2021-07-01 to 2021-09-30	19,848,108	shares	92
2021-01-01 to 2021-09-30	17,864,604	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.12	USD/shares	92
2022-01-01 to 2022-09-30	-0.4	USD/shares	273
2021-07-01 to 2021-09-30	-0.22	USD/shares	92
2021-01-01 to 2021-09-30	-0.76	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.12	USD/shares	92
2022-01-01 to 2022-09-30	-0.4	USD/shares	273
2021-07-01 to 2021-09-30	-0.22	USD/shares	92
2021-01-01 to 2021-09-30	-0.76	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-09-30	52,355	USD
At 2021-12-31	58,149	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	2,640,349	USD	273
2021-01-01 to 2021-09-30	3,356,859	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-3,187,693	USD	92
2022-01-01 to 2022-09-30	-10,077,109	USD	273
2021-07-01 to 2021-09-30	-4,063,528	USD	92
2021-01-01 to 2021-09-30	-13,307,587	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	6,773,269	USD
At 2021-12-31	6,461,605	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	1,326,952	USD
At 2021-12-31	2,722,390	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	278,200	USD
At 2021-12-31	286,192	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2022-09-30	248,971	USD
At 2021-12-31	248,971	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-09-30	4,618	USD
At 2021-12-31	5,041	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	3,187,693	USD	92
2022-01-01 to 2022-09-30	10,077,109	USD	273
2021-07-01 to 2021-09-30	4,063,528	USD	92
2021-01-01 to 2021-09-30	13,307,587	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,243,556	USD	92
2022-01-01 to 2022-09-30	3,040,024	USD	273
2021-07-01 to 2021-09-30	1,691,688	USD	92
2021-01-01 to 2021-09-30	6,062,360	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	26,853,962	shares
At 2021-12-31	20,946,712	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	66,190,027	USD
At 2021-12-31	54,429,979	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2022-09-30	207,471	USD
At 2021-12-31	246,209	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2022-09-30	955,405	USD
At 2021-12-31	2,376,930	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2022-09-30	504,104	USD
At 2021-12-31	389,501	USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

Period	Value	Unit	Days
At 2022-09-30	23,399	USD
At 2021-12-31	23,399	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-3,109,350	USD	92
2022-01-01 to 2022-09-30	-9,864,721	USD	273
2021-07-01 to 2021-09-30	-4,317,784	USD	92
2021-01-01 to 2021-09-30	-13,592,482	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	423	USD	273
2021-01-01 to 2021-09-30	423	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	78,343	USD	92
2022-01-01 to 2022-09-30	212,388	USD	273
2021-07-01 to 2021-09-30	-254,256	USD	92
2021-01-01 to 2021-09-30	-284,895	USD	273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2021-01-01 to 2021-09-30	6,954	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	9,123,741	USD	273
2021-01-01 to 2021-09-30	10,950,005	USD	273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	52,595	USD	273
2021-01-01 to 2021-09-30	45,146	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-9,289	USD	273
2021-01-01 to 2021-09-30	-464,459	USD	273

Inspect the source

Entity: Adial Pharmaceuticals, Inc. / CIK 0001513525
Captured: 2026-09-20T09:13:16.139Z
SEC response SHA-256: a18f3033034427d32ef6db390e21f05d7acd23d932b720bc7458a3fbeee3e90d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001513525.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))